Atacicept is a TACI-Fc fusion protein and dual BAFF/APRIL inhibitor indicated to reduce proteinuria in adults with primary IgA nephropathy at risk for progression. Atacicept is a recombinant fusion glycoprotein that joins the ligand-binding portion of the human TACI receptor to a modified IgG1 Fc domain, allowing it to bind and neutralize two cytokines: B cell activating factor (BAFF)...
- Mechanism
- Curator reviewed
Atacicept contains the soluble TACI receptor that binds to the cytokines BLyS and APRIL. These cytokines are members of the tumor necrosis factor family that promote B-cell survival and autoantibody production associated with certain autoimmune diseases such as systemic lupus erythematosus. Current data indicates that levels of BLyS and APRIL are elevated in patients with rheumatoid arthritis, lupus erythematosus, B-cell malignancies and multiple sclerosis. Atacicept has been shown to affect several stages of B-cell development and may inhibit the survival of cells responsible for making antibodies.
- Primary indication
- Atacicept is indicated to reduce proteinuria in adults with primary immunoglobulin A nephropathy (IgAN) at risk for disease progression.Curator reviewed · 1 structured indication
- First approval
- United States, 2026
- Also known as
- Atacicept-vymj
- Code names
- VT-001
- Brand names
Resolves to
What you can answer from here — as of August 20, 2026
Which drugs share a target with Atacicept, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account